[ Symic Biomedical raises $30M in Series B ]
Symic Biomedical has raised $30 million in Series B funding.
Founded in 2012, Symic Biomedical operates in the healthcare industry focusing on biotechnology business. It develops pipeline products for targeting the extracellular matrix.
The company will use the new financing to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures.
|Founder / CEO||Kenneth N. Horne|
|Previous Investors||Lilly Ventures|
|Mitsui Global Investment|
|National Institutes of Health|